Remove 2019 Remove Chemotherapy Remove Pharmaceutical Companies
article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study.

article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

Pharmaceutical companies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Innate Pharma has also partnered with Takeda to develop an antibody drug conjugate (ADC). percent, reaching even 57.1 percent in the skin.

article thumbnail

The GoCART Coalition: Guidance for pharmacists

Hospital Pharmacy Europe

GoCART aims to promote patient access to novel cellular therapies, bringing together different stakeholders, including healthcare professionals, health authorities, pharmaceutical companies, patient representatives, health technology assessment bodies, reimbursement agencies and medical non-profit organisations.

article thumbnail

2022 ISPE Annual Meeting & Expo Opening Keynotes Focus on Quality, Transformation, and Patients

ISPE

Quality management maturity (QMM) entered the discussion on ways to address the challenges in 2019 in the FDA report, “ Drug Shortages: Root Causes and Potential Solutions. ” The trial at that time involved high doses of vitamin D with chemotherapy, and began with chemo, then surgery, recuperation, more chemo, and finally radiation.

FDA 98
article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

million direct deaths in 2019 and an additional 4.95 If left unchecked, it may soon not be possible to use antibiotics as prophylaxis for immunocompromised patients during chemotherapy or organ transplants. AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them.